Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Direxion Daily Healthcare Bull 3X Shares (CURE): Leveraged Exposure to the Healthcare Sector

Direxion Daily Healthcare Bull 3X Shares (CURE): Leveraged Exposure to the Healthcare Sector

Key Takeaways

  • CURE is a leveraged exchange-traded fund (ETF) that seeks daily investment results equal to 300% of the performance of the Health Care Select Sector Index.
  • It is issued by Direxion and launched on June 15, 2011, trading on the NYSE Arca exchange.
  • The fund is designed for short-term, tactical investors, not buy-and-hold investors, because leveraged returns reset daily.
  • CURE provides amplified exposure to large U.S. healthcare companies, including pharmaceuticals, biotechnology, and health care providers.
  • Its net expense ratio is approximately 0.94%, and it uses derivatives such as swaps to achieve its leveraged objective.

Understanding the CURE ETF

The Direxion Daily Healthcare Bull 3X Shares, trading under the ticker CURE, is a leveraged exchange-traded fund (ETF) that offers investors a way to express a strongly bullish view on the U.S. healthcare sector. Rather than providing one-to-one exposure to healthcare stocks, CURE aims to deliver three times (300%) the daily return of its benchmark index. This makes it a high-octane vehicle used mainly by experienced, short-term traders who want amplified sector exposure without purchasing individual stocks on margin. When assessing similar leveraged products, I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

ETF Overview and Investment Strategy

CURE is a passively managed, leveraged ETF issued by Direxion, a specialist provider of geared and inverse funds. The fund seeks daily investment results, before fees and expenses, of 300% of the performance of the Health Care Select Sector Index (IXV), a benchmark maintained by S&P Dow Jones Indices. The index is a market-capitalization-weighted sub-index of the S&P 500 that captures domestic companies across the healthcare industry, including pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, life sciences tools and services, and health care technology.

To achieve its leveraged investment objective, CURE does not simply buy three times the value of healthcare stocks. Instead, it invests at least 80% of its net assets in financial instruments — most notably equity index swaps and other derivatives — that, in combination, provide 3X daily leveraged exposure to the index. The fund is advised by Rafferty Asset Management, LLC, and is considered non-diversified under the Investment Company Act of 1940. I reviewed the strategy details through Tickeron’s AI Daily Buy/Sell Signals to confirm alignment with short-term tactical approaches.

CURE was launched on June 15, 2011, and holds a relatively concentrated portfolio. Depending on the reporting source and date, the fund has held roughly 60 to 80 positions, with its largest exposures concentrated in a handful of dominant healthcare names. Its net expense ratio is approximately 0.94%, which is higher than a typical unleveraged sector ETF, reflecting the cost of managing derivatives and maintaining daily leverage.

Portfolio Holdings and Sector Exposure

Because CURE tracks the Health Care Select Sector Index, its portfolio holdings are dominated by large-cap U.S. healthcare leaders. As of recent reporting periods, the largest index constituents — and therefore the fund's most significant exposures — have typically included LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), AMGN (Amgen), and GILD (Gilead Sciences).

Effectively, 100% of the fund's equity exposure is allocated to the healthcare sector. This concentrated sector exposure means CURE's performance is driven almost entirely by the fortunes of the broader healthcare complex, from drug development and medical devices to insurers and hospitals. The fund also maintains a meaningful cash position to support its swap-based leverage structure.

Why Investors Follow CURE

CURE attracts attention primarily from active traders and tactical investors who want to amplify short-term moves in healthcare stocks. Healthcare is a sector with distinct macroeconomic drivers, including demographic aging, innovation in pharmaceuticals and biotechnology, and regulatory developments around drug pricing and healthcare policy. For investors who hold a strong near-term conviction about these themes, CURE offers a liquid, exchange-traded way to magnify that view. One thing that stands out is how the fund can also serve as a tactical portfolio tool for hedging or speculation, though its role is fundamentally different from a traditional diversified ETF. Its 3X daily leverage means even modest daily moves in the underlying index are multiplied threefold, which can generate outsized gains — or losses — over very short holding periods.

Risks and Important Considerations

CURE carries risks that go well beyond those of a standard healthcare ETF. The most important is the effect of daily rebalancing. Because the fund resets its leverage each day, its returns over periods longer than a single day can diverge significantly from three times the cumulative return of the index. In volatile, choppy markets, this "volatility decay" can erode performance even when the underlying index is flat or modestly higher. Investors should also consider the fund's expense ratio, its reliance on swap counterparties, and its concentrated, non-diversified structure. The healthcare sector itself is sensitive to regulation, litigation, patent expirations, and government reimbursement policies. Leverage amplifies all of these risks. CURE is generally considered unsuitable for long-term buy-and-hold investors and is intended only for sophisticated traders who can monitor positions closely. From what I see, this makes ongoing monitoring essential.

Conclusion

The Direxion Daily Healthcare Bull 3X Shares stands apart from conventional sector ETFs because of its aggressive, daily-reset leverage. While it offers a powerful tool for expressing short-term, bullish views on U.S. healthcare, its structure demands careful risk management and a clear understanding of how leveraged products behave over time. For traders seeking amplified healthcare exposure, CURE remains a notable and closely watched instrument within the leveraged ETF universe. I’m watching this closely for any shifts in sector momentum.

Integrating Tickeron’s AI Screener Into Research

In my own analysis of leveraged ETFs like CURE, Tickeron’s AI Screener has become a practical resource. It helps surface comparable ideas across sectors using technical indicators, fundamentals, and AI-generated signals, allowing me to quickly evaluate whether a position fits broader tactical strategies without sifting through thousands of options manually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CURE

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


CURE's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for CURE moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In 29 of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CURE as a result. In 91 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for CURE turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

CURE moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for CURE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURE advanced for three days, in 288 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

CURE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 229 of 248 cases where CURE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Health Care Select Sector Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology. It is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily Healthcare Bull 3X ETF (CURE) ETF is 117.06B. The market cap for tickers in the group ranges from 9.59B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is HSIC at 9.59B.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily Healthcare Bull 3X ETF (CURE) ETF was 6%. For the same ETF, the average monthly price growth was 26%, and the average quarterly price growth was 339%. A experienced the highest price growth at 1%, while UNH experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily Healthcare Bull 3X ETF (CURE) ETF was 33%. For the same stocks of the ETF, the average monthly volume growth was 3% and the average quarterly volume growth was 20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 45
Price Growth Rating: 30
SMR Rating: 58
Profit Risk Rating: 69
Seasonality Score: 32 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.